Targeting specific receptors in neuroblastoma treatment
Official title: NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management
Funded at Nanopharmaceuticals, LLC · NIH-11004741 · Data updated 2026-11-12
This study is testing a new way to treat neuroblastoma in young children by using a special compound that helps deliver cancer-fighting medicine directly to the tumor, with the hope of making existing treatments work better and improving survival for kids with high-risk cases.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanopharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Rensselaer, United States) |
| Project start | September 19, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $792,367 |
| NIH project number | 1R44CA287485-01A1 |
| Project ID | NIH-11004741 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under the age of 5 who have been diagnosed with high-risk neuroblastoma.
✕Less likely to help
Patients with low-risk neuroblastoma or those older than 5 years may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for neuroblastoma, a common cancer in young children. The approach involves creating a dual-targeting ligand that can effectively bind to specific receptors on cancer cells, enhancing the delivery of therapeutic agents. By targeting the integrin αvβ3 and norepinephrine transporter, the treatment aims to improve the effectiveness of existing therapies and potentially increase survival rates for high-risk patients. The research utilizes advanced nanotechnology to create a compound that can deliver anticancer actions directly to the tumor.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for children with high-risk neuroblastoma.
How similar studies have gone: While the approach of dual targeting in cancer treatment is promising, this specific application in neuroblastoma is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Nanopharmaceuticals, LLC
Rensselaer, United States Active
Researchers
- Principal investigator: Davis, Paul — Nanopharmaceuticals, LLC
- Study coordinator: Davis, Paul
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.